VYNE Therapeutics (VYNE) Leases (2019 - 2025)
VYNE Therapeutics' Leases history spans 6 years, with the latest figure at $32000.0 for Q2 2025.
- For Q2 2025, Leases fell 78.81% year-over-year to $32000.0; the TTM value through Jun 2025 reached $32000.0, down 78.81%, while the annual FY2024 figure was $93000.0, 55.07% down from the prior year.
- Leases reached $32000.0 in Q2 2025 per VYNE's latest filing, down from $62000.0 in the prior quarter.
- In the past five years, Leases ranged from a high of $1.4 million in Q1 2021 to a low of $32000.0 in Q2 2025.
- Average Leases over 4 years is $451500.0, with a median of $165500.0 recorded in 2024.
- Peak YoY movement for Leases: fell 18.25% in 2021, then crashed 78.81% in 2025.
- A 4-year view of Leases shows it stood at $1.0 million in 2021, then crashed by 80.02% to $207000.0 in 2023, then tumbled by 55.07% to $93000.0 in 2024, then crashed by 65.59% to $32000.0 in 2025.
- Per Business Quant, the three most recent readings for VYNE's Leases are $32000.0 (Q2 2025), $62000.0 (Q1 2025), and $93000.0 (Q4 2024).